Listing of the Claims:

The following listing of Claims will replace all prior versions and listings of Claims in the Application.

Claims:

1. (original) A compound of the formula



I

wherein the molecular weight of the compound of formula I is less than 1000 AMU;

X is $>CH_2$ >NH, sulfur, >S=O, $>SO_2$ or oxygen; wherein said $>CH_2$ and >NH may optionally be substituted with a suitable substituent;

R^1 is selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl and other suitable substituents;

R^2 is selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl and other suitable substituents;

s is an integer from 0-4;

R^3 is R^4, R^5-(NR^6)-, R^5-S-, R^5-(S=O)-, R^5-(SO_2)-, R^5-SO_2-NR^6-, R^5-(NR^6)-SO_2-, R^5-O-, R^5-(C=O)-, R^5-(NR^6)-(C=O)-, R^5-(C=O)-NR^6-, R^5-O-(C=O)-, R^5-(C=O)-O-, R^5-CR^7=CR^8- or R^5-C≡C-;

such that the molecular weight of R^3 is less than 500 AMU;

R^4, R^5 and R^6 are each selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl and other suitable substituents;

wherein the molecular weight of the compound of formula I is less than 1000 AMU;

or a pharmaceutically acceptable salt thereof.

2. (original) A compound of the formula



I

wherein R^1 is selected from the group of substituents consisting of hydrogen, -C≡N, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkyny- l, $(C_3$-$C_{10})$cycloalkyl, phenyl, $(C_1$-$C_{10})$heteroaryl, $(C_1$-$C_{10})$heterocyclic and $(R^{17})_2$ -N-; wherein each of the aforesaid $(C_1$-$C_6)$alkyl, $(C_3$-$C_{10})$cycloalkyl, phenyl, $(C_1$-$C_{10})$heteroaryl and $(C_1$-$C_{10})$heterocyclic substituents may optionally be independently substituted by one to four moieties independently selected from the group consisting of halo, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkyny- l, perhalo$(C_1$-$C_6)$alkyl, phenyl, $(C_3$-$C_{10})$cycloalkyl, $(C_1$-$C_{10})$heteroaryl, $(C_1$-$C_{10})$heterocyclic, formyl,-C≡N, $(C_1$-$C_6)$alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, $(C_1$-$C_6)$alkyl -O-(C=O)-, $(C_1$-$C_6)$alkyl-NH-(C=O)-, $[(C_1$-$C_6)$alkyl$]_2$ N-(C=O)-, phenyl-NH-(C=O)-, phenyl-$[((C_1$-$C_6)$alkyl)-N]-(C=O)-, -NO_2, amino, $(C_1$-$C_6)$alkylamino, $[(C_1$-$C_6)$alkyl$]_2$-amino, $(C_1$-$C_6)$alkyl-(C=O)-NH-, $(C_1$-$C_6)$alkyl-(C=O)-$[((C_1$-$C_6)$alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-$[(C_1$-$C_6)$alkyl)-N]-, H_2N-(C=O)-NH-, $(C_1$-$C_6)$alkyl-HN-(C=O)-NH-, $[(C_2$-$C_6)$alkyl$]_2$-N-(C=O)-NH-, $(C_1$-$C_6)$alkyl-HN-(C=O)-$[((C_1$-$C_6)$alkyl)-N]-, $[(C_1$-$C_6)$alkyl$]_2$-N-(C=O)-$[(C_1$-$C_6)$alkyl)- N]-, phenyl-HN-(C=O)-NH-, $(phenyl)_2$-N-(C=O)-NH-, phenyl-HN-(C=O)-$[((C_1$-$C_6)$alkyl)-N]-, $(phenyl)_2$-N-(C=O)-$[((C_1$-$C_6)$alkyl)N]-, $(C_1$-$C_6)$alkyl-O-(C-O)-NH-, $(C_1$-$C_6)$alkyl-O-(C=O)-$[(C_1$-$C_6)$alkyl)-N]-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-$[(C_1$-$C_6)$alkyl)-N]-, $(C_1$-$C_6)$alkyl-SO_2NH-, phenyl-SO_2NH-, $(C_1$-$C_6)$alkyl-SO_2-, phenyl-SO_2-, hydroxy, $(C_1$-$C_6)$alkoxy, perhalo$(C_1$-$C_6)$alkoxy, phenoxy, $(C_1$-$C_6)$alkyl-(C=O)-O-, phenyl-(C=O)-O-, H_2N-(C=O)-O-, $(C_1$-$C_6)$alkyl-HN-(C=)-O-, $[(C_1$-$C_6)$alkyl$]_2$-N-(C=O)-O-, phenyl-HN-(C=O)-O- and $(phenyl)_2$-N-(C=O)-O-; wherein when said R^1 phenyl substituent contains two adjacent moieties, such moieties may optionally be taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; wherein each of said moieties containing a phenyl alternative may optionally be substituted by one or two radicals independently selected from the group consisting of $(C_1$-$C_6)$alkyl, halo, $(C_1$-$C_6)$alkoxy, perhalo$(C_1$-$C_6)$alkyl and perhalo$(C_1$-$C_6)$alkoxy;

s is an integer from zero to four;

each R^2 is independently selected from the group consisting of hydrogen, halo, (C_1-C_4)alkyl, and $-CF_3$;

R^3 is R^4, R^5-(NR^6)-, R^5-S-, R^5-(S=O)-, R^5-(SO_2)-, R^5- SO_2-NR^6-, $R^5(NR^6)SO_2$-, R^5-O-, R^5-(C=O)R^5-(NR^6)-(C=O)-, R^5 (C=O)-NR^6-, R^5-O-(C=O)-, R^5 (C=O)-O-, R^5-CR^7=CR^8- or R^5-C≡C-;

R^4 is hydrogen, halo, -C≡N, $(R^9)_m$-(C_1-C_6)alkyl, $(R^9)_m$-(C_2-C_6)alkenyl, perhalo(C_1-C_6)alkyl, $(R^9)_m$-phenyl, $(R^9)_m$ -(C_1-C_{10})heteroaryl, $(R^9)_m$ -(C_1-C_{10})heterocyclic, or $(R^9)_m$ -(C_3-C_{10})cycloalkyl,

R^5 is hydrogen, -C≡N, $(R^9)_m$-(C_1-C_6)alkyl- , $(R^9)_m$-(C_2-C_6)alkenyl, $(R^9)_m$-(C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, $(R^9)_m$-phenyl, $(R^9)_m$-(C_1-C_{10})heteroaryl, $(R^9)_m$-(C_1-C_{10})heterocyclic, or $(R^9)_m$-(C_3-C_{10})cycloalkyl;

m is an integer from one to three; R^6 is selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_3-C_{10})cycloalkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, R^{13}-(C=O)-, and R^{13}-(SO_2)-;

wherein each of the aforesaid (C_1-C_6)alkyl, (C_3-C_{10})cycloalkyl, phenyl, (C_1-C_{10})heteroaryl and (C_1-C_{10})heterocyclic substituents may optionally be independently substituted on any carbon atom by one to four moieties per substituent independently selected from the group consisting of halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_3-C_{10})cycloalkyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, formyl, -C≡N, (C_1-C_6)alkyl -(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl -O-(C=O)-, (C_1-C_6)alkyl -NH-(C=O)-, (C_1-C_6)alkyl$]_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C_1-C_6)alkyl)-N]-(C=O)-, $-NO_2$, amino, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl$]_2$-amino, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[(C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]- , H_2N-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-NH-, [(C_1-C_6)alkyl$]_2$-N-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-[(((C_1-C_6)alkyl)-N]-, [(C_1-C_6)alkyl$]_2$-N-(C=O)-[(((C_1-C_6)alkyl)-N]-, phenyl-HN-(C=O)-NH-, (phenyl$)_2$-N-(C=O)-NH-, phenyl-HN-(C=O)-[(((C_1-C_6)alkyl)-N]-, (phenyl-$)_2$-N-(C=O)-[(((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-O-(C=O)-NH-, (C_1-C_6)alkyl-O-(C=O)-[(C_1-C_6)alkyl)-N]-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[(C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-SO_2NH-, phenyl-SO_2NH-, (C_1-C_6)alkyl -SO_2-, phenyl-SO_2-, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_1-C_6)alkyl-(C=O)-O-, phenyl-(C=O)-O-, H_2N- (C=O)- O-, (C_1-C_6)alkyl-HN-(C=O)-O-, [(C_1-C_6)alkyl$]_2$-N-(C=O)-O-, phenyl-HN-(C=O)-O-, and (phenyl$)_2$-N-(C=O)- O-;

wherein when said R^6 phenyl substituent contains two adjacent moieties, such moieties may optionally be taken together with the carbon atoms to which they are

attached to form a five to six membered carbocyclic or heterocyclic ring; wherein each of said moieties containing a phenyl alternative may optionally be substituted by one or two radicals independently selected from the group consisting of (C_1-C_6)alkyl, halo, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkyl and perhalo(C_1-C_6)alkoxy; R^7 is selected from the group consisting of hydrogen, (C_1-C_6)alky, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, and (C_3-C_{10})cycloalkyl; R^8 is hydrogen, or (C_1-C_6)alkyl; wherein when R^9 is a substituent on a carbon atom each R^9 is independently selected from the group consisting of hydrogen, halo, R^{11}-(C_1-C_6)alkyl, R^{11}-(C_2-C_6)alkenyl, R^{11}-(C_2-C_6)alkynyl, azido, perhalo(C_1-C_6)alkyl, (C_1-C_6)alkyl-S-, (C_1 - C_6)alkyl-SO_2-, R^{11}-[$N(R^{10})$]-SO_2-, -NO_2, (R^{11})$_2$-N-, R^{11}-SO_2-[$N(R^{10})$]-, R^{11}- (C=O)-[$N(R^{10})$]-, (R^{11})-[$N(R^{10})$]-(C=O)-[$N(R^{10})$]-, R^{11}-O-(C=O) -[$N(R^{10})$]-, -C≡N, R^{11}-(C=O)-, R^{11}-O-(C=O)-, (R^{11})-[$N(R^{10})$]-(C=O)-, R^{11}-O-, perhalo(C_1-C_6)alkoxy, R^{11}-(C=O)-O-, R^{11}-O- (C=O)- O- and (R^{11})-[$N(R^{10})$]-(C=O)-O-;

wherein when R^9 is a substituent on a nitrogen atom each R^9 is independently selected from the group consisting of hydrogen, R^{11}-(C_1-C_6)alkyl, R^{11}-(C_2-C_6)alkenyl, R^{11}-(C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, (C_1-C_6)alkyl-SO_2-, R^{11}-[$N(R^{10})$]-SO_2-, R^{11}-(C=O)-, R^{11}-O-(C=O)- and (R^{11})- [$N(R^{10})$]-(C=O)-; R^{10} is hydrogen or (C_1-C_4)alkyl; R^{11} is selected from the group consisting of hydrogen, R^{12}-(C_1-C_6)alkyl, (C_3-C_6)alkenyl, (C_3-C_6)alkynyl, (C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl; wherein each of the aforesaid R^{12}-(C_1-C_6)alkyl, (C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently selected from halo, -C≡N, (C_1-C_6)alkyl, (C_1-C_6)alkyl-O-(C=O)-, and (C_1-C_6)alkoxy;

R^{12} is selected from the group consisting of hydrogen, hydroxy, (C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl; wherein each of the aforesaid (C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently selected from halo, -C=N, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy;

R^{13} is selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkyny- l, perhalo(C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_1-C_{10})heteroaryl-O-, (C_1-C_{10})heterocyclic-O-, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, amino, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, (C_1-

C_6)alkyl-(C=O)- NH-, (C_1-C_6)alkyl-(C=O)-[(C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, and phenyl-(C=O)-[((C_1-C_6)alkyl)-N-]-;

X is >C(R^{14})$_2$, >NR^{15}, sulfur, >S=O, > SO_2 or oxygen;

each R^{14} is independently selected from the group consisting of hydrogen, halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, (C_1-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_1-C_{10})heteroaryl-O-, (C_1-C_{10})heterocyclic-O-, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-, -NO_2, amino, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, (C_1-C_6)alkyl -(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, -C-N, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, (C_1-C_{10})heteroaryl-(C=O)-, (C_1-C_{10})heterocyclic-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C_1-C_6)alkyl)-N]-(C=O)-, (C_1-C_{10})heteroaryl-NH-(C=O)-, (C_1-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)- and (C_1-C_6)alkyl-(C=O)-O-; wherein two R^{14} substituents may be optionally taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring;

R^{15} is selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_3-C_{10})cycloalkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, R^{16}-(C=O)-, and R^{16}-(SO_2)-; wherein each of the aforesaid (C_1-C_6)alkyl, (C_1-C_{10})cycloalkyl, phenyl, (C_1-C_{10})heteroaryl and (C_1-C_{10})heterocyclic substituents may optionally be independently substituted on any carbon atom by one to four moieties per substituent independently selected from the group consisting of halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_3-C_{10})cycloalkyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, formyl, -C≡N, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, -NO_2, amino, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-(C=O)-N H-, (C_1-C_6)alkyl-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]- , H_2N-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-NH-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-[((C_1-C_6)alkyl)-N]-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-HN-(C=O)-NH-, (phenyl)$_2$-N-(C=O)-NH-, phenyl-HN-(C=O)-[((C_1-C_6)alkyl)-N]-, (phenyl-)$_2$N-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-O-(C=O)-NH-, (C_1-C_6)alkyl-O-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-SO_2NH-, phenyl-SO_2NH-, (C_1-C_6)alkyl-SO_2-,

phenyl-SO_2-, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_1-C_6)alkyl-(C=O)-O-, phenyl-(C=O)-O-, H_2N-(C=O)-O-, (C_1-C_6)alkyl-HN-(C=O)-O-, [(C_1-C_6)alkyl]$_2$-N-(C=O)- O-, phenyl-HN- (C=O)-O-, and (phenyl)$_2$N-(C=O)-O-; wherein each of the aforesaid (C_1-C_{10})heteroaryl and (C_1-C_{10})heterocyclic substituents may optionally be independently substituted on any nitrogen atom by a substituent selected from the group consisting of (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_3-C_{10})cycloalkyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, formyl, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_1-C_6)alkyl-SO_2- and phenyl-SO_2-; wherein when said R^{15} phenyl substituent contains two adjacent moieties, such moieties may optionally be taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; wherein each of said moieties containing a phenyl alternative may optionally be substituted by one or two radicals independently selected from the group consisting of (C_1-C_6)alkyl, halo, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkyl and perhalo(C_1-C_6)alkoxy;

R^{16} is selected from the group consisting of hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, (C_1-C_6)alkoxy and perhalo(C_1-C_6)alkoxy;

each R^{17} is independently selected from hydrogen, (C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic and (C_3-C_{10})cycloalkyl; wherein each of the aforesaid R^{17} substituents (C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl- , (C_1-C_{10})heterocyclic and (C_3-C_{10})cycloalkyl may optionally be substituted on any carbon atom by one to four moieties per substituent independently selected from the group consisting of halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkyny- l, perhalo(C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_1-C_{10})heteroaryl-O-, (C_1-C_{10})heterocyclic-O-, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-,-NO_2, amino, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[(C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[(C_1-C_6)alkyl)-N]-, -C≡N, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, (C_1-C_{10})heteroaryl-(C=O)-, (C_1-C_{10})heterocyclic-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-(C_1-C_6)alkyl-NH-(C=O)- [(C_1-C_6)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl (C_1-C_6)alkyl)-N]-(C=O)-, (C_1-C_{10})heteroaryl-NH-(C=O)-, (C_1-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-, (C_1-C_6)alkyl-(C=O)-O- and phenyl-(C=O)-O-; wherein each of the aforesaid R^{17}

substituents (C_1-C_{10})heteroaryl and (C_1-C_{10})heterocyclic may optionally be substituted on any nitrogen atom by a moiety selected from the group consisting of (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, (C_1-C_{10})heteroaryl-(C=O)-, (C_1-C_{10})heterocyclic-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)- (C_1-C_6)alkyl-NH-(C=O)-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C_1-C_6)alkyl)-N]-(C=O)-, (C_1-C_{10})heteroaryl-NH-(C=O)-, (C_1-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-, (C_1-C_6)alkyl-(C=O)-O- and phenyl-(C=O)-O-; wherein two R^{17} (C_1-C_6)alkyl groups may be taken together with the nitrogen atom to which they are attached to form a five to six membered heterocyclic or heteroaryl ring;

or a pharmaceutically acceptable salt thereof.

3. (original) A compound according to claim 2, wherein R^3 is R^4.

4. (original) A compound according to claim 3, wherein R^4 is hydrogen, halo, -C≡N or perhalo(C_1-C_6)alkyl.

5. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-(C_1-C_6)alkyl.

6. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-phenyl, $(R^9)_m$-(C_1-C_{10})heteroaryl, $(R^9)_m$-(C_1-C_{10})heterocyclic or $(R^9)_m$-(C_3-C_{10})cycloalkyl.

7. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-(C_1-C_6)alkyl; m is 1; R^9 is selected from the group consisting of hydrogen, halo, R^{11}-(C_1-C_6)alkyl, R^{11}-(C_2-C_6)alkenyl, R^{11}-(C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, R^{11}-[$N(R^{10})$]-SO_2-, -NO_2, R^{11}-SO_2-[$N(R^{10})$]-, -C≡N, and perhalo(C_1-C_6)alkoxy.

8. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-(C_1-C_6)alkenyl; m is 1; R^9 is selected from the group consisting of hydrogen, halo, R^{11}-(C_1-C_6)alkyl, R^{11}-(C_2-C_6)alkenyl, R^{11}-(C_2-C_6)alkyny-, perhalo(C_1-C_6)alkyl, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, R^{11}-[$N(R^{10})$]-SO_2-, -NO_2, R^{11}-SO_2-[$N(R^{10})$]-, -C≡N, and perhalo(C_1-

C_6)alkoxy.

9. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-(C_1-C_6)alkyl; m is 1; R^9 is selected from the group consisting of $(R^{11})_2N$-, R^{11}-(C=O)-[$N(R^{10})$]-, (R^{11})-[$N(R^{10})$]-(C=O)-[$N(R^{10})$]-, R^{11}-O-(C=O)-[$N(R^{10})$]-, R^{11}-(C=O)-, R^{11}-O-(C=O)-, (R^{11})-[$N(R^{10})$]-(C=O)-, R^{11}-O-, R^{11}-(C=O)-O-, R^{11}-O-(C=O)-O- and (R^{11})-[$N(R^{10})$]-(C=O)-O-.

10. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$- (C_1-C_6)alkyl; m is 1; R^9 is selected from the group consisting of $(R^{11})_2N$-, R^{11}-(C=O)-[$N(R^{10})$]-, (R^{11})-[$N(R^{10})$]-(C=O)-[$N(R^{10})$] -, R^{11}-O-(C=O)-[$N(R^{10})$]-, R^{11}-(C=O)-, R^{11}-O-(C=O)-, (R^{11})-[$N(R^{10})$]-(C=O)-, R^{11}-O-, R^{11}-(C=O)-O-, R^{11}-O-(C=O)-O- and (R^{11})-[$N(R^{10})$]-(C=O)-O-; and R^{11} is selected from the group selected from hydrogen, R^{12}-(C_1-C_6)alkyl, (C_3-C_6)alkenyl, and (C_3-C_6)alkynyl.

11. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-(C_1-C_6)alkyl; m is 1; R^9 is selected from the group consisting of R^{11}-(C=O)-[$N(R^{10})$]-, (R^{11})-[$N(R^{10})$]-(C=O)-[$N(R^{10})$]-, R^{11}-O-(C=O)-[$N(R^{10})$]-, R^{11}-(C=O)-, R^{11}-O-(C=O)-, (R^{11})-[$N(R^{10})$]-(C=O)-, R^{11}-O-, R^{11}-(C=O)-O-, R^{11}-O-(C=O)- O- and (R^{11})-[$N(R^{10})$]-(C=O)-O-; and R^{11} is selected from the group selected from (C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl; wherein each of the aforesaid (C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently selected from halo, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy.

12. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-(C_1)alkyl; m is 1; R^9 is selected from the group consisting of hydrogen, halo, R^{11}-(C_1-C_6)alkyl, R^{11}-(C_2-C_6)alkenyl, R^{11}-(C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, R^{11}-[$N(R^{10})$]-SO_2-, -NO_2, R^{11}-SO_2-[$N(R^{10})$]-, -C≡N, and perhalo(C_1-C_6)alkoxy; and R^{11} is selected from the group consisting of (C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl; wherein each of the aforesaid C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently selected from halo, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy.

13. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-(C_1)alkyl; m is 1; R^9 is selected from the group consisting of $(R^{11})_2N$-, R^{11}-(C=O)-[$N(R^{10})$]-, (R^{11})-[$N(R^{10})$]-(C=O)-[$N(R^{10})$]-, R^{11}-O-(C=O)-[$N(R^{10})$]-, R^{11}-(C=O)-, R^{11}-O-(C=O)-, (R^{11})-[$N(R^{10})$]-(C=O)-, R^{11}-O-, R^{11}-(C=O)-O-, (R^{11}-O-(C=O)-O- and (R^{11})-[$N(R^{10})$]-(C=O)-O-; and R^{11} is hydrogen, R^{12}-(C_1-C_6)alkyl, (C_3-C_6)alkenyl, and (C_3-C_6)alkynyl.

14. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-(C_1)alkyl; m is 1; R^9 is selected from the group consisting of $(R^{11})_2N$-, R^{11}-(C=O)-[$N(R^{10})$]-, (R^{11})-[$N(R^{10})$]-(C=O)-[$N(R^{10})$]-, R^{11}-O-(C=O)-[$N(R^{10})$]-, R^{11}-(C=O)-, R^{11}-O-(C=O)-, (R^{11})-[$N(R^{10})$]-(C=O)-, R^{11}-O-, R^{11}-(C=O)-O-, R^{11}-O-(C=O)-O- and (R^{11})-[$N(R^{10})$]-(C=O)-O-; and R^{11} is selected from the group selected from (C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl; wherein each of the aforesaid (C_1-C_{10})heterocyclic, (C_1-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, and phenyl substituents may optionally be substituted with one to three moieties independently selected from halo, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy.

15. (original) A compound according to claim 3, wherein R^4 is $(R^9)_m$-(C_1)alkyl; m is 1; R^9 is selected from the group consisting of R^{11}-(C=O)-[$N(R^{10})$]-, (R^{11})-[$N(R^{10})$]-(C=O)-($N(R^{10})$]-, R^{11}-O-(C=O)-[$N(R^{10})$]-, R^{11}-(C=O)-, R^{11}-O-(C=O)-, (R^{11})-[$N(R^{10})$]-(C=O)-, R^{11}-O-, R^{11}-(C=O)-O-, R^{11}-O-(C=O)-O- and (R^{11})-[$N(R^{10})$]-(C=O)-O-; and R^{11} is selected from the group consisting of hydrogen, R^{12}-(C_1-C_6)alkyl and (C_1-C_{10})heteroaryl; wherein each of the aforesaid (C_1-C_6)alkyl and (C_1-C_{10})heteroaryl substituents may optionally be substituted with one to three moieties independently selected from halo, (C_1-C_6)alkyl, and (C_1-C_6)alkoxy.

16. (currently amended) A compound according to ~~any of the previous~~ claims 2 wherein X is $>C(R^{14})_2$.

17. (currently amended) A compound according to claims ~~1-15~~ 2 wherein X is $>NR^{15}$.

18. (currently amended) A compound according to claims ~~1-15~~ 2 wherein X is -S-

19. (currently amended) A compound according to claims ~~1-15~~ 2 wherein X is >S=O.

20. (currently amended) A compound according to claims ~~1-15~~ 2 wherein X is $>SO_2$.

21. (currently amended) A compound according to claims ~~1-15~~ 2 wherein X is -O-.

22. (currently amended) A compound according to ~~any of the previous~~ claims 2 wherein R^1 is optionally substituted (C_1-C_6)alkyl, phenyl, (C_3-C_{10})cycloalkyl, (C_1-C_{10})heteroaryl or (C_1-C_{10})heterocyclic.

23. (currently amended) A compound according to claims ~~1-21~~ 2 wherein R^1 is (C_1-C_6)alkyl, optionally substituted with one to four groups independently selected from halo, hydroxy, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkoxy, -C≡N, $-NO_2$, amino, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, HO-(C=O)-, (C_1-C_6)alkyl-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, (C_1-C_6)alkyl-CO_2-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-NH-(C=O)-, (C_1-C_6)alkyl-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_1-C_6)alkyl-SO_2NH-, (C_1-C_6)alkyl-SO_2-, optionally substituted phenyl-(C=O)-, optionally substituted phenyl-(C=O)-O-, optionally substituted phenoxy, optionally substituted phenyl-NH-(C=O)-, optionally substituted phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, optionally substituted phenyl-(C=O)-NH- and optionally substituted phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-.

24. (currently amended) A compound according to claims ~~1-21~~ 23 wherein R^1 is (C_1-C_4)alkyl.

25. (currently amended) A compound according to claims ~~1-21~~ 23 wherein R^1 is optionally substituted (C_3-C_6)cycloalkyl.

26. (currently amended) A compound according to claims ~~1-21~~ 23 wherein R^1 is optionally substituted phenyl.

27. (currently amended) A compound according to claims ~~1-21~~ 26 wherein R^1 is optionally substituted phenyl wherein said substituents are independently selected from the group consisting of halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, perhalo(C_1-C_6)alkyl, -C≡N, (C_1-C_6)alkyl-(C=O) -, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, $[(C_1-C_6)alkyl]_2$-N-(C=O)-, amino, (C_1-C_6)alkylamino, $[(C_1-C_6)alkyl]_2$-amino, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)- -[((C1-C6)alkyl)-N]-, H_2N-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-NH-, $[(C_1-C_6)alkyl]_2$N-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-[((C_1-C_6)alkyl)-N]-, $[(C_1-C_6)alkyl]_2$-N-(C=O)-[((C_1-C_6)alkyl)-N]-, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, (C_1-C_6)alkyl-(C=O)-O-, H_2N-(C=O)-O-, (C_1-C_6)alkyl-HN-(C=O)-O- and $[(C_1-C_6)alkyl]_2$-N-(C=O)-O-.

28. (original) A compound according to claim 26 wherein R^1 is optionally substituted phenyl containing two adjacent substituents which taken together with the carbon atoms to which they are attached form a five to six membered carbocyclic or heterocyclic ring.

29. (currently amended) A compound according to claims ~~1-21~~ 2 wherein R^1 is $(R^{17})_2$-N-, wherein each R^{17} is independently selected from hydrogen, (C_1-C_6)alkyl, phenyl, (C_1-C_{10})heterocyclic and (C_3-C_{10})cycloalkyl; wherein each of the aforesaid R^{17}, (C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl, (C_1-C_{10})heterocyclic and (C_3-C_{10})cycloalkyl substituents may optionally be substituted by one to four moieties independently selected from the group consisting of halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_1-C_{10})heteroaryl, (C1-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_1-C_{10})heteroaryl-O-, (C_1-C_{10})heterocyclic-O-, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C6)alkyl-SO_2-, (C_1-C_6)alkyl-NH- SO_2-, -NO_2, amino, (C_1-C_6)alkylamino, $[(C_1-C_6)alkyl]_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, -C≡N, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, (C_1-C_{10})heteroaryl-(C=O)-, (C_1-C_{10})heterocyclic- (C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-, (C1-C_6)alkyl-NH-(C=O)-, $[(C_1-C_6)alkyl]_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_1-C_{10})heteroaryl-NH-(C=O)-, (C_1-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-, (C_1-C_6)alkyl-(C=O)-O- and phenyl-(C=O)-O-; wherein two R^2 (C_1-C_6)alkyl groups may be taken together with the nitrogen atom to form a five to six membered heterocyclic or heteroaryl

ring;

30. (original) A compound according to claim 29 wherein R^1 is $(R^{17})_2$-N- and wherein each R^{17} is independently selected from hydrogen, $(C_1$-$C_4)$alkyl, phenyl and $(C_1$-$C_{10})$heterocyclic.

31. (original) A compound according to claim 29 wherein R^1 is $(R^{17})_2$-N- and wherein two R^2 $(C_1$-$C_6)$alkyl groups may be taken together with the nitrogen atom to form a five to six membered heterocyclic or heteroaryl ring.

32. (currently amended) A compound according to ~~any of the previous~~ claims 2, wherein s is an integer from one to four and each R^2 is independently selected from the group consisting of halo, -C≡N, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl and perhalo$(C_1$-$C_6)$alkyl.

33. (currently amended) A compound according to claims ~~1-31~~ 2, wherein s is an integer from one to four and zero, one or two of R^2 are independently selected from the group consisting of halo, $(C_1$-$C_6)$alkyl, perhalo$(C_1$-$C_6)$alkyl, hydroxy, $(C_1$-$C_6)$alkoxy, perhalo$(C_1$-$C_6)$alkoxy, amino, $(C_1$-$C_6)$alkylamino, $[(C_1$-$C_6)$alkyl$]_2$-amino, -C=N, and $H_2N(C=O)$-.

34. (currently amended) A compound according to claims ~~1-31~~ 2, wherein s is an integer from one to three and each R^2 is independently selected from the group consisting of halo, $(C_1$-$C_6)$alkyl, perhalo$(C_1$-$C_6)$alkyl- , hydroxy, $(C_1$-$C_6)$alkoxy, perhalo$(C_1$-$C_6)$alkoxy, $-NO_2$, amino, $(C_1$-$C_6)$alkylamino, $[(C_1$-$C_6)$alkyl$]_2$-amino, -C≡N, and $H_2N(C=O)$-.

35. (currently amended) A compound according to claims ~~1-31~~ 2, wherein s is an integer from one to two and each R^2 is independently selected from the group consisting of halo, $(C_1$-$C_6)$alkyl, perhalo$(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, perhalo$(C_1$-$C_6)$alkoxy and -C≡N.

36. (original) A compound according to claim 35, wherein s is an integer from one to three and each R^2 is independently selected from the group consisting of fluoro,

chloro and methyl.

37. (currently amended) A compound according to claim 2, wherein said compound is selected from the group consisting of:

1-Ethyl-3-[2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl]-urea;

Ethyl-carbamic acid 2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl ester;

[2-(3-Isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl]-carbamic acid ethyl ester;

1-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-3-[2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl]-urea;

Ethyl-carbamic acid 2-(3-tert-butyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl ester;

1-(5-tert-Butyl-isoxazol-3-yl)-3-[2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl]-urea;

Ethyl-carbamic acid 5-fluoro-2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl ester;

Ethyl-carbamic acid 2-fluoro-6-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-benzyl ester; and

N-Ethyl-3-[2-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]-acrylamide~~;~~ .

38. (withdrawn) A method of treating an ERK/MAP kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to any of the previous claims.

39. (withdrawn) A method of treating a p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to any of the previous claims.

40. (withdrawn) A method for treating a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic

shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, ischemic necrosis, myocardial infarct, stroke burns, thrombosis, glomerularonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a human, comprising administering to said mammal an amount of a compound according to any of the previous claims, effective in treating such a condition.

41. (withdrawn) A pharmaceutical composition for the treatment of a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerularonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a human, comprising an amount of a compound according to any of the previous claims effective in such treatment and a pharmaceutically acceptable carrier.

42. (withdrawn) A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of ERK/MAP kinase in a mammal, including a human, comprising an amount of a compound according to any of the previous claims effective in such treatment and a pharmaceutically acceptable carrier.

43. (withdrawn) A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of p38 kinase in a mammal, including a

human, comprising an amount of a compound according to any of the previous claims effective in such treatment and a pharmaceutically acceptable carrier.